Neurol. praxi. 2017;18(3):186-189 | DOI: 10.36290/neu.2017.026

B cells as a target in the treatment of multiple sclerosis

MUDr. Luděk Hochmuth
Ambulancia alergológie a klinickej imunológie, II. interná klinika SZU a FNsP F. D. Roosevelta, Banská Bystrica

B cells play important role in pathogenesis of multiple sclerosis. Pathogenic mechanisms include antigen presentation, pro- and

anti-inflammatory cytokines production, B cells can differentiate to plasmatic cells producing autoantibodies and they can participate

on creation of meningeal follicular structures in central nervous system (CNS). We can effectively influence the course

of disease by therapeutic depletion through anti-CD20 antibodies. Efficacy and safety of this treatment were demonstrated in

clinical studies with relapsing remitting and primary progressive multiple sclerosis.

Keywords: multiple sclerosis, B cells, anti-CD20 monoclonal antibodies, therapy

Received: June 7, 2017; Accepted: June 7, 2017; Published: July 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hochmuth L. B cells as a target in the treatment of multiple sclerosis. Neurol. praxi. 2017;18(3):186-189. doi: 10.36290/neu.2017.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alexopoulos H, Biba A, Dalakas MC. Anti-B-cell therapies in autoimmune neurological diseases: rationale and efficacy trials. Neurotherapeutics 2016; 13: 20-33. Go to original source... Go to PubMed...
    2. Bar-Or A, Grove R, Austin D, Tolson J, Vanmeter S, Lewis E, Sorensen PS. The MIRROR study: a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and mri efficacy of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosis (RRMS). Neurology 2014; 82(10): Supplement S23.006. Go to original source...
    3. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, Fan B, O'Connor RA, Anderton SM, Bar-Or A, Fillatreau S, Gray D. B cell depletion therapy ameliorates autoimmune disease through ablation of Il-6-producing B cells. J Exp Med 2012; 209: 1001-1010. Go to original source... Go to PubMed...
    4. Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol 1998; 161: 3299-3306. Go to original source...
    5. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA. CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380: 1819-28. Go to original source... Go to PubMed...
    6. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA. CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380: 1829-1839. Go to original source... Go to PubMed...
    7. Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH. A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS). Neurology 2007; 68(12): Suppl. 1: A99-A100.
    8. Hauser SL, Comi GC, Hartung H-P, Selmaj K, Traboulsee A, Bar-Or A, Arnold DL, Klingelschmitt G, Kakarieka A, Lublin F, Garren H, Kappos L. On behalf of the OPERA I and II clinical investigators. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis - results of the interferon-beta-1a-controlled, double blind, phase III OPERA I and II studies. Mult Scler 2015; 21(Suppl.): 61-2 [Abstract 190].
    9. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH. OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471. Go to original source... Go to PubMed...
    10. Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, Tremlett H. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain 2012; 135: 2973-2979. Go to original source... Go to PubMed...
    11. Koziolek M, Tampe D, Bahr M, Dihazi H, Jung K, Fitzner D, Klingel R, Müller GA, Kitze B. Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation 2012; 9: 80-89. Go to original source... Go to PubMed...
    12. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 2012; 8: 613-623. Go to original source... Go to PubMed...
    13. Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, Fan B, Ouamara N, Johnson TA, Rajasekharan S, Bar-Or A. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol 2012; 246: 85-95. Go to original source... Go to PubMed...
    14. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717. Go to original source... Go to PubMed...
    15. Luhder F, Graold R. Trial and error in clinical studies: lessons from ATAMS. Lancet Neurol 2014; 13: 340-341. Go to original source... Go to PubMed...
    16. Mayer MC, Hohlfeld R, Meinl E. Viability of autoantibody-targets: how to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis. J Neurol Sci 2012; 319(1-2): 2-7. Go to original source... Go to PubMed...
    17. Milo R. Therapeutic strategies targeting B-cells in multiple sclerosis. Autoim Reviews 2016; 15(7): 714-718. Go to original source... Go to PubMed...
    18. Montalban X, Hemmer B, Rammohan K, Giovannoni G, de Seze J, Bar-Or A, Arnold DL, Sauter A, Kakarieka A, Masterman D, Chin P, Garren H, Wolinsky J. On behalf of the ORATORIO clinical investigators. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, phase III ORATORIO study. Mult Scler 2015; 21(Suppl.): 781-2 [Abstract 228].
    19. Nielsen NM, Rostgaard K, Rasmussen S, Koch-Henriksen N, Storm HH, Melbye M, Hjalgrim H. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 2006; 118: 979-984. Go to original source... Go to PubMed...
    20. Rao S, Sancho J, Campos-Rivera J, Boutin P, Severy P, Weeden T, Shankara S, Roberts BL, Kaplan JM. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012; 7: e39416. Go to original source... Go to PubMed...
    21. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14: 164-174. Go to original source... Go to PubMed...
    22. Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, Drulovic J, Filippi M. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014; 82: 573-581. Go to original source... Go to PubMed...
    23. Stangel M, Fredrikson S, Meinl E, Petzold A, Stuve O, Tumani H. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol 2013; 9: 267-276. Go to original source... Go to PubMed...
    24. Von Budingen HC, Kuo TC, Sirota M, Van Belle CJ, Apeltsin L, Glanville J, Cree BA, Gourraud PA, Schwartzburg A, Huerta G, Telman D, Sundar PD, Casey T, Cox DR, Hauser SL. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest 2012; 122: 4533-4543. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.